Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL5952367

N.N#Cc1ccc(N)c(N)c1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 1/20 0.48
GAA P10253 1/20 0.48
TDP1 Q9NUW8 3/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.39
CYP3A4 P08684 2/20 0.39
ALOX15 P16050 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP2A6 P11509 2/20 0.39
TSHR P16473 2/20 0.39
TP53 P04637 1/20 0.39
THRB P10828 1/20 0.39
CA12 O43570 1/20 0.39
CA2 P00918 1/20 0.39
CA3 P07451 1/20 0.39
CA6 P23280 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352155 0.97 ALDH1A1 (0.50) ALDH1A1KDM4EGAATDP1MEN1
SCHEMBL29443092 0.97 ALDH1A1 (0.50) ALDH1A1KDM4EGAATDP1MEN1
SCHEMBL11277214 0.97 ALDH1A1 (0.50) ALDH1A1KDM4EGAATDP1MEN1
SCHEMBL21277388 0.80 ALDH1A1 (0.44) ALDH1A1KDM4EGAALOXL2CYP2A6
SCHEMBL29655663 0.79 TDP1 (0.61) ALDH1A1TDP1MEN1KMT2ALOXL2
SCHEMBL15156687 0.79 TDP1 (0.61) ALDH1A1TDP1MEN1KMT2ALOXL2
SCHEMBL30702253 0.78 ALDH1A1 (0.43) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL3440802 0.78 ALDH1A1 (0.43) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL98131 0.78 TTR (0.48) ALDH1A1KDM4EGAALOXL2CYP2A6
SCHEMBL2419320 0.78 ALDH1A1 (0.47) ALDH1A1KDM4EGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 US disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 US disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 ALDH1A1 1389/4885KDM4E 522/4885GAA 264/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A ALDH1A1 862/4885KDM4E 645/4885GAA 352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.